sensitivity between 89.5 and 96.9% for rifampin and 82.1 and 89.3% for isoniazid and reported specificity ranging from 86.2 to 94.3% for rifampin and from 88.0 to 95.1% for isoniazid. Early identification of pathogen susceptibility to rifampin and isoniazid using TB-biochips results in a significantly better tretment outcome because of the introduction of adequate drug therapy at the earliest stages of treatment. The TB-BIOCHIP MDR test identifies more mutations responsible for resistance to rifampicin and isoniazid than any other commercially available test. Computerized registration and processing of the results yield unambiguous conclusions, excluding human error. Another system TB-BIOCHIP FQ allows detection of mutations in the gyrA gene responsible for resistance to fluoroquinolones (FQ). Using TB-BIOCHIP FQ system it was shown that the proportion of patients with resistance infection did not exceed 2% among newly diagnosed TB cases, whereas this proportion was 10% or even more among chronic patients with already identified multidrug-resistant disease. The sensitivity and specificity of the "TB-Biochip FQ" test was determined in clinical trials and reached 81 and 96%, respectively. 2) reinforce new case detection mechanism; (3) improve numbers of TB and MDR cases to be cured; and (4) strengthen international collaboration. Research focus can be divided in the following areas: (1) understanding the epidemiology of tuberculosis, including enhancement of surveillance system and development of new molecular methods, for evaluating factors influencing the occurrence and transmission of Mycobacterium tuberculosis; (2) revealing the basic biology of host and M. tuberculosis, including genetic analysis of host and different lineages of strains; (3) assessing and developing new TB diagnostics, including development of improved diagnostic tools for early TB and drug-resistant diagnosis and differentiating nontuberculous mycobacteria; (4) improving and defining effective treatment of TB and MDR TB, including evaluation of new lead compounds and candidate antibiotics against M. tuberculosis using laboratory assays, and supporting research on drug-resistant mechanisms; (5) developing laboratory quality-assurance systems, including certification and timely reporting of laboratory services. Progress of research has contributed to shaping TB program in Taiwan, and more efforts are needed for better TB control.
Tuberculosis (TB) is a leading infectious disease in Taiwan; 13,200 new cases, including 164 multidrug-resistant (MDR), were confirmed in the year of 2010. A program of "Halving TB Prevalence in Ten Years" has been implemented by Taiwan Centers for Disease Control since 2006; which formulated 4 major strategies: (1) amend existing national TB control program; (2) reinforce new case detection mechanism; (3) improve numbers of TB and MDR cases to be cured; and (4) strengthen international collaboration. Research focus can be divided in the following areas: (1) understanding the epidemiology of tuberculosis, including enhancement of surveillance system and development of new molecular methods, for evaluating factors influencing the occurrence and transmission of Mycobacterium tuberculosis; (2) revealing the basic biology of host and M. tuberculosis, including genetic analysis of host and different lineages of strains; (3) assessing and developing new TB diagnostics, including development of improved diagnostic tools for early TB and drug-resistant diagnosis and differentiating nontuberculous mycobacteria; (4) improving and defining effective treatment of TB and MDR TB, including evaluation of new lead compounds and candidate antibiotics against M. tuberculosis using laboratory assays, and supporting research on drug-resistant mechanisms; (5) developing laboratory quality-assurance systems, including certification and timely reporting of laboratory services. Progress of research has contributed to shaping TB program in Taiwan, and more efforts are needed for better TB control. doi:10.1016/j.phrp.2011.11.034 S10 Abstracts
